Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Benjamin Scirica MD

Benjamin Morgan Scirica MD

Senior Physician and Director, Innovation, Cardiovascular Division, Brigham and Women's Hospital; Professor of Medicine, Harvard Medical School; Senior Investigator, TIMI Study Group, Boston, Massachusetts

Dr. Benjamin Scirica is a senior physician and Director of Innovation in the Cardiovascular Division at Brigham and Women's Hospital and Professor of Medicine at Harvard Medical School. He is a Senior Investigator at the TIMI Study Group (an academic research organization based at Brigham and Women's Hospital that has performed over 75 clinical trials in cardiometabolic diseases).

His research interests center on the risk stratification, management, and the identifation of novel therapies to improve outcomes in patients with acute coronary syndromes and cardiometabolic disorders. 

Dr. Scirica has authored or co-authored over 200 peer-reviewed articles and is a reviewer for multiple journals, including The New England Journal of Medicine, JAMA, The Lancet, Circulation, and Journal of the American College of Cardiology (JACC).

Disclosures

  • Institutional research support to Brigham and Women’s Hospital from: Amgen; Better Therapeutics; Boehringer Ingelheim; Merck; Novo Nordisk; Pfizer; Verve Therapeutics
  • Consulting fees from: AbbVie (DSMB); Amgen; AstraZeneca (DSMB); Bayer; Boehringer Ingelheim (DSMB); Elsevier Practice Update Cardiology; Hanmi (DSMB); Lexeo (DSMB); Novo Nordisk; Verve Therapeutics; and equity in Health [at] Scale; Arboretum Lifescience

Recent Contributions to PracticeUpdate:

  1. Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
  2. Mechanisms of Sodium-Glucose Cotransporter 2 Inhibitors
  3. 2019 Top Stories in Cardiology: The DAPA-HF Study
  4. Heart Failure Risk Stratification and Efficacy of SGLT2 Inhibitors in Patients With Type 2 Diabetes
  5. Targeted Temperature Management for Cardiac Arrest With Nonshockable Rhythm
  6. DEFINE-HF: Outcomes in Patients With HFrEF Treated With Dapagliflozin
  7. Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction
  8. Association of Metabolic Surgery With MACE in Patients With Type 2 Diabetes and Obesity
  9. ESC 2019: Recommendations From Dr. Ben Scirica
  10. Effects of Alirocumab on Types of MI

Most Read This Week

Recently Updated